Vera Therapeutics, Inc. Shareholders' Equity
Vera Therapeutics, Inc. (VERA) had Shareholders' Equity of $407.76 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $407.76M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $499.70M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $604.52M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $398.88M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $407.76M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $499.70M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $604.52M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $398.88M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $468.28M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $535.00M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $577.15M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $289.06M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $327.87M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $353.54M 10-Q · filed 2025-11-05 |
| 2023-12-31 | $101.69M 10-K · filed 2026-02-26 |
| 2023-09-30 | $123.71M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $140.52M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $157.71M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $76.91M 10-K · filed 2026-02-26 |
| 2022-09-30 | $105.72M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $121.50M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $134.43M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $69.59M 10-K · filed 2024-03-27 |
| 2021-09-30 | $85.48M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $92.16M 10-Q · filed 2022-11-09 |
| 2021-03-31 | -$93.32M 10-Q · filed 2022-11-09 |
| 2020-12-31 | -$89.35M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$46.88M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$42.47M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$38.95M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$36.55M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |